Stephanie Leigh

Paralegal Specialist
Full contact info

Experience

Alani Nu’s $1.8 Billion Sale to Celsius

February 20, 2025

Cooley advised Katy Hearn and Haydn Schneider, co-founders of Alani Nu, in connection with Celsius Holdings’ (Nasdaq: CELH) definitive agreement to acquire the company for $1.8 billion in cash and stock.

Read more

Related contacts

Bill Roegge
Partner, New York
Stephanie Leigh
Paralegal Specialist, San Diego
Stephanie Gentile
Partner, New York
Jeremy Morrison
Partner, Washington, DC
Vicky Kandabarow
Associate, Washington, DC
Kyle Hess
Associate, New York
Wesley Dietrich
Associate, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Todd Gluth
Partner, San Diego
Sarah Lightdale
Partner, New York
Eileen Marshall
Partner, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Julia R. Brinton
Special Counsel, Washington, DC
William Corcoran
Of Counsel, Boston

Related Practices & Industries

Poseida Therapeutics – $80.5 Million Follow-on Offering

September 7, 2022

Cooley advised the issuer for Poseida Therapeutics’ $80.5 million follow-on offering of 23,000,000 shares of common stock at a public offering price of $3.50 per share. Poseida is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next-generation cell and gene therapeutics. Partners Tom Coll and Charlie Kim led the Cooley team.

Related contacts

Tom Coll
Partner, San Diego
Charlie Kim
Partner, San Diego
Asa Henin
Partner, San Diego
Edmond Lay
Partner, San Diego
Heidi E. Wang
Associate, San Diego
Stephanie Leigh
Paralegal Specialist, San Diego
Kelly Nelle
Paralegal Specialist, San Diego

Related Practices & Industries

Kronos Bio – $288 million IPO

October 8, 2020

Cooley advised Kronos Bio on its $287.5 million initial public offering of 15,131,579 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Kronos Bio, whose securities now trade on the Nasdaq Global Select Market under the symbol KRON, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. Partners Charles Bair, Charlie Kim and Chad Mills led the Cooley team.

Related contacts

Charles Bair
Partner, San Diego
Chadwick Mills
Partner, San Francisco
Asa Henin
Partner, San Diego
Brett Dovman
Associate, San Diego
Stephanie Leigh
Paralegal Specialist, San Diego
Kate Walther
Paralegal Specialist, San Diego

Related Practices & Industries